Glycopyrrolate Injection Vials Recalled Due to Labeling Mix-up
HF Acquisition Co LLC is recalling Glycopyrrolate Injection 0.2mg/mL due to a label mix-up affecting specific lots distributed in Texas, Arizona, and California.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III drug recall involving a labeling error with no reported illnesses or injuries. Per the severity rubric, minor labeling errors are typically scored as Moderate (2).
Plain-English summary
HF Acquisition Co LLC is recalling Glycopyrrolate Injection, USP 0.2mg/mL in 1mL vials because of a label mix-up. The recalled product is Lot #2205095.1, which expires July 31, 2024. The recall involves 9 boxes containing 25 vials each.
The product was distributed to Texas, Arizona, and California. Healthcare facilities and patients who have this product should contact HF Acquisition Co LLC or their distributor for instructions on return and replacement.
The recalled product
- Product
- GLYCOPYRROLATE (GLYCOPYRROLATE)
- Brand
- GLYCOPYRROLATE
- Manufacturer
- HF Acquisition Co LLC
- Hazard
- label-mix-up
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 2205095.1
- Exp. Date 7/31/2024
Distribution
Distributed in 3 states:
- AZ
- CA
- TX
Related recalls
Same brand · GLYCOPYRROLATE
- ModerateGlycopyrrolate Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2023-06-28
- HighGlycopyrrolate Injection Recalled Due to Manufacturing Quality Deviations
FDA (Drugs) · 2023-03-08
- ModerateGlycopyrrolate injection recalled due to manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- HighGlycopyrrolate Injection, USP recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- HighPrescription Glycopyrrolate Injection Recalled Due to Manufacturing Process Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateClomiphene Citrate USP Active Pharmaceutical Ingredient Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-15
- SevereBortezomib for Injection Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15
- ModerateGasco Isopropyl Alcohol 70% recalled nationwide for subpotency
FDA (Drugs) · 2026-07-15